Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Heparin industry 360º synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Product trends
2.1.4 Source trends
2.1.5 Application trends
2.1.6 Distribution channel trends
Chapter 3 Heparin Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of chronic diseases
3.2.1.2 High demand for anticoagulants products
3.2.1.3 Rising geriatric population across the globe
3.2.2 Industry pitfalls & challenges
3.2.2.1 High risk of side effects
3.2.2.2 High dependency on porcine
3.3 Growth potential analysis
3.3.1 By product
3.3.2 By source
3.3.3 By application
3.3.4 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Heparin Market Size and Forecast, By Product (USD Million)
5.1 Key trends, by product
5.2 Low molecular weight heparin
5.3 Unfractionated heparin
Chapter 6 Heparin Market Size and Forecast, By Source (USD Million)
6.1 Key trends, by source
6.2 Porcine
6.3 Bovine
Chapter 7 Heparin Market Size and Forecast, By Application (USD Million)
7.1 Key trends, by application
7.2 Venous thromboembolism
7.3 Atrial fibrillation/flutter
7.4 Coronary artery disease
7.5 Other applications
Chapter 8 Heparin Market Size and Forecast, By Distribution Channel (USD Million)
8.1 Key trends, by distribution channel
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy
Chapter 9 Heparin Market Size and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Austria
9.3.7 Poland
9.3.8 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Amphastar
10.2 Leo Pharma
10.3 Pfizer
10.4 Rovi
10.5 Sanofi
10.6 Shenzhen Hepalink
10.7 Changzhou Qianhong Biopharma
10.8 Nanjing King-Friend Biochemical Pharmaceutical
10.9 Yantai Dongcheng Biochemicals Co., Ltd.
10.10 Fresenius Kabi
